BMN

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Retrieved on: 
Wednesday, October 27, 2021
Legal, Professional Services, Safety, Complaint, BMRN, BMN, Certification, Ethics, SEC Rule 10b-5, NASDAQ, Suite, FDA, U.S. Securities and Exchange Commission, Company, BioMarin Pharmaceutical, Securities Exchange Act of 1934, Security (finance)

Investors who purchased the Company's securities between January 13, 2020, and September 3, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before December 21, 2021.

Key Points: 
  • Investors who purchased the Company's securities between January 13, 2020, and September 3, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before December 21, 2021.
  • If you are a shareholder who suffered a loss, click here to participate .
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, October 26, 2021
Legal, Professional Services, Safety, Complaint, BMRN, BMN, Certification, Ethics, SEC Rule 10b-5, NASDAQ, Suite, FDA, U.S. Securities and Exchange Commission, Company, BioMarin Pharmaceutical, Securities Exchange Act of 1934, Security (finance)

Investors who purchased the Company's securities between January 13, 2020, and September 3, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before December 21, 2021.

Key Points: 
  • Investors who purchased the Company's securities between January 13, 2020, and September 3, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before December 21, 2021.
  • If you are a shareholder who suffered a loss, click here to participate .
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Tuesday, October 26, 2021
Legal, Professional Services, Safety, BMRN, PKU, Phenylketonuria, BMN, PAH, History, Lawyer, Patient, Private Securities Litigation Reform Act, NASDAQ, FDA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CASE, Clinical trial, BioMarin Pharmaceutical, SEC, News, Enron, Securities Exchange Act of 1934, Lists of schools in England, Tobacco, Pharmaceutical industry

If you wish to serve as lead plaintiff of the BioMarin class action lawsuit, please provide your information by clicking here .

Key Points: 
  • If you wish to serve as lead plaintiff of the BioMarin class action lawsuit, please provide your information by clicking here .
  • Lead plaintiff motions for the BioMarin class action lawsuit must be filed with the court no later than December 21, 2021.
  • A lead plaintiff acts on behalf of all other class members in directing the BioMarin class action lawsuit.
  • An investors ability to share in any potential future recovery of the BioMarin class action lawsuit is not dependent upon serving as lead plaintiff.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN

Retrieved on: 
Monday, October 25, 2021
Legal, Professional Services, Titan, Court, LinkedIn, BMRN, BMN, Twitter, THE, NASDAQ, FDA, Food, Class, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, I-Space (Chinese company), WHY, Facebook, BioMarin Pharmaceutical, Advertising, Lists of schools in England, TO, Tobacco, Insurance

WHAT TO DO NEXT: To join the BioMarin class action, go to http://www.rosenlegal.com/cases-register-2185.html or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioMarin class action, go to http://www.rosenlegal.com/cases-register-2185.html or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceutical Inc. (BMRN)

Retrieved on: 
Monday, October 25, 2021
Safety, Complaint, BMRN, BMN, PAH, SEC Rule 10b-5, NASDAQ, FDA, Company, BioMarin Pharmaceutical, District court, News, GLOBE, Securities Exchange Act of 1934, Pharmaceutical industry

The Company advised investors that [t]he FDAs clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study.

Key Points: 
  • The Company advised investors that [t]he FDAs clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study.
  • Investors who purchased or otherwise acquired shares of BioMarin should contact the Firm prior to the December 21, 2021 lead plaintiff motion deadline.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Corporate Presentation Uranium Vision 2020

Retrieved on: 
Friday, April 17, 2020
Nuclear materials, Physical sciences, Materials, Nuclear technology, Uranium, Nuclear fuels, Uranium market, BMN, Bannerman

PERTH, Australia, April 17, 2020 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN, OTCQB:BNNLF, NSX:BMN) (Bannerman or the Company) is pleased to provide an updated Corporate Presentation.

Key Points: 
  • PERTH, Australia, April 17, 2020 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN, OTCQB:BNNLF, NSX:BMN) (Bannerman or the Company) is pleased to provide an updated Corporate Presentation.
  • Geopolitical implications, in particular for China
    Bannermans Chief Executive Officer, Mr Brandon Munro, said, Bannerman is ideally positioned to withstand the current global market uncertainties, yet react positively to improvements in the uranium market as COVID-19 uranium supply disruption continues or expands.
  • We have a strong cash balance, low cash burn and an advanced, permitted project a combination that provides both extended operating runway without the need for additional capital and market-leading leverage to positive uranium dynamics.
  • This announcement was authorised to be issued by the Managing Director.

MEMBRANE STUDY SUCCESS AND CORPORATE UPDATE

Retrieved on: 
Wednesday, April 8, 2020
BMN, Leverage, Bannerman, Humans

PERTH, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN, OTCQB:BNNLF, NSX:BMN) (Bannerman or the Company) is pleased to provide an update on the successful completion of the Etango project Membrane Study and corporate actions taken to maintain the Companys strong balance sheet.

Key Points: 
  • PERTH, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN, OTCQB:BNNLF, NSX:BMN) (Bannerman or the Company) is pleased to provide an update on the successful completion of the Etango project Membrane Study and corporate actions taken to maintain the Companys strong balance sheet.
  • We have a strong cash balance, low cash burn and an advanced, permitted project a combination that provides both extended operating runway without the need for additional capital and market-leading leverage to positive uranium dynamics.
  • This announcement was authorised to be issued by the Board of Directors.
  • For further information please contact: